Last updated: September 5, 2026
The formulation comprising polyethylene glycol 3350, potassium chloride, sodium bicarbonate, sodium chloride and anhydrous sodium sulfate is the electrolyte bowel-preparation product commonly identified with GoLYTELY and generic polyethylene glycol-electrolyte solutions. The product is an established prescription laxative used for colon cleansing before colonoscopy and other gastrointestinal procedures.
Its commercial profile is mature rather than growth-driven. The market has low clinical differentiation, extensive generic availability, limited patent protection and recurring procedure volume tied to colonoscopy demand. Revenue is exposed to generic price competition, payer substitution, lower-volume split-dose regimens and branded alternatives such as Suprep, Sutab and Clenpiq.
What drug is identified by this active-ingredient combination?
The ingredient combination corresponds to an isotonic polyethylene glycol-electrolyte lavage solution.
| Component |
Function |
| Polyethylene glycol 3350 |
Osmotic laxative that retains water in the bowel |
| Sodium sulfate, anhydrous |
Electrolyte and osmotic cleansing agent |
| Sodium chloride |
Replaces sodium and chloride ions |
| Potassium chloride |
Replaces potassium ions |
| Sodium bicarbonate |
Buffers the solution and supplies bicarbonate |
GoLYTELY is supplied as a powder for oral solution. After reconstitution, the solution is consumed in a large volume, commonly 4 liters, under a split-dose or procedure-specific regimen. The formulation is designed to produce rapid bowel evacuation while limiting net electrolyte and water exchange through an electrolyte-balanced solution.[1]
The FDA-approved product is associated with Braintree Laboratories, a Bausch Health company. Multiple generic manufacturers market therapeutically equivalent polyethylene glycol 3350 and electrolyte solutions.
What is the FDA regulatory status of polyethylene glycol 3350 electrolyte solution?
The reference product is approved under NDA 018097. It is a prescription bowel-cleansing product, not an over-the-counter product, when marketed as the prescription electrolyte lavage formulation.[1]
FDA regulatory milestones
| Regulatory item |
Status |
| Reference product |
GoLYTELY |
| Active ingredients |
PEG 3350, sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate |
| Dosage form |
Powder for oral solution |
| FDA pathway |
Original NDA and subsequent abbreviated generic approvals |
| Reference NDA |
018097 |
| Therapeutic category |
Laxative; bowel-cleansing agent |
| Primary use |
Preparation of the colon for colonoscopy and related procedures |
| Pediatric use |
Label-specific and age-dependent |
| Prescription status |
Prescription product |
Generic versions are generally approved through ANDA procedures as therapeutically equivalent products. FDA labeling emphasizes contraindications including gastrointestinal obstruction, ileus, gastrointestinal perforation, toxic megacolon and severe hypersensitivity. Fluid and electrolyte abnormalities remain relevant safety considerations, particularly in patients with renal, cardiac or hepatic disease.[1]
When does GoLYTELY lose exclusivity?
GoLYTELY has already lost practical market exclusivity. The product was approved decades ago, and any original small-molecule regulatory exclusivity has expired.
The commercial exclusivity position is defined by generic entry rather than by a pending loss date. Generic polyethylene glycol-electrolyte lavage products are available from several manufacturers, including large generic suppliers and private-label distributors.
Exclusivity timeline
| Event |
Commercial effect |
| Original FDA approval |
Established the reference product |
| Expiration of original regulatory exclusivity |
Opened the market to ANDA applicants |
| Generic approvals |
Created therapeutic substitution and price competition |
| Current market |
Mature, multi-source generic category |
| Remaining protection |
Primarily trademarks, branding, packaging, manufacturing know-how and distribution relationships |
There is no commercially material orphan-drug, pediatric, biologic or NCE exclusivity protecting the formulation today.
What patents protect GoLYTELY and generic PEG-electrolyte solutions?
The active-ingredient combination has limited current patent relevance. The formulation is an old osmotic-electrolyte bowel preparation, and generic competitors have entered the market.
Patent estate assessment
| Protection category |
Current commercial relevance |
| Composition-of-matter patents |
No material live protection expected for the core formulation |
| Original formulation patents |
Expired or commercially ineffective against approved generic equivalents |
| Method-of-use patents |
Limited relevance; bowel cleansing before gastrointestinal procedures is established use |
| Manufacturing patents |
Possible process know-how, but generally weak as a barrier to ANDA competition |
| Packaging patents |
Potentially narrow and avoidable |
| Trademark protection |
Relevant to GoLYTELY brand recognition |
| Trade secrets |
Relevant to manufacturing economics but not a direct market-exclusion right |
The Orange Book should be reviewed for the current listing status of NDA 018097 before making a litigation or launch decision. The market position of GoLYTELY is not dependent on a broad, enforceable patent monopoly.
What is the Orange Book status of GoLYTELY?
GoLYTELY is an FDA-approved prescription drug listed under NDA 018097. The commercial importance of any Orange Book patent listing is limited because the market already includes generic versions.
An Orange Book entry can still affect an ANDA applicant if a patent is listed with a valid expiration date and the applicant must submit a Paragraph IV certification. That procedural possibility does not establish meaningful market exclusivity. For this mature bowel-prep formulation, the principal barriers are regulatory filing costs, manufacturing scale, customer contracts and channel access.
How many patents cover polyethylene glycol 3350 electrolyte solution?
The core formulation is not protected by a meaningful active patent estate comparable to newer branded gastrointestinal products. Any relevant patent count depends on the search date, jurisdiction, formulation interpretation and whether expired, abandoned or narrow process patents are included.
A practical competitive assessment is:
| Patent area |
Risk level |
| Core composition |
Low |
| Standard oral lavage use |
Low |
| Split-dose administration |
Low to moderate, depending on claim scope |
| Flavoring and packaging |
Low |
| Manufacturing process |
Low to moderate |
| Device-enabled administration |
Low for the standard product |
| Trademark and trade dress |
Moderate for branded substitution, low for generic entry |
Patent risk is therefore lower than regulatory and commercial execution risk.
Which companies compete in the PEG 3350 electrolyte market?
Competition occurs across three groups: branded high-volume lavage solutions, generic PEG-electrolyte solutions and lower-volume bowel-preparation products.
Direct competitors
- Bausch Health and Braintree Laboratories: GoLYTELY and related PEG-electrolyte products.
- Generic manufacturers: suppliers of PEG 3350, sodium sulfate, sodium chloride, potassium chloride and sodium bicarbonate solutions.
- Salix Pharmaceuticals: Plenvu, a lower-volume PEG-based product with a different formulation.
- Sebela Pharmaceuticals: Sutab, an oral sulfate tablet.
- Braintree Laboratories: Suprep, a sulfate-based liquid preparation.
- Ferring Pharmaceuticals: Clenpiq, a lower-volume sodium picosulfate product.
The main competitive distinction is not active-ingredient mechanism. It is the amount of liquid required, tolerability, taste, completion rate, prescriber preference, payer coverage and procedure-center workflow.
How does GoLYTELY compare with Suprep, Sutab and Plenvu?
| Product |
Primary formulation |
Volume burden |
Commercial positioning |
| GoLYTELY |
PEG 3350 plus electrolytes |
High, commonly 4 L |
Established, low-cost reference and generic category |
| Suprep |
Sodium sulfate, potassium sulfate and magnesium sulfate |
Lower product volume plus additional water |
Branded convenience and tolerability positioning |
| Sutab |
Sulfate-based tablets |
Tablets plus substantial water |
Tablet-based convenience |
| Plenvu |
PEG-based lower-volume solution |
Lower than traditional 4-L PEG solutions |
Lower-volume PEG alternative |
| Clenpiq |
Sodium picosulfate, magnesium oxide and citric acid |
Lower product volume plus water |
Convenience-oriented branded alternative |
GoLYTELY and its generics retain a cost advantage and long clinical familiarity. Lower-volume and tablet products compete on patient acceptance and completion, despite higher acquisition costs in many channels.
What is the financial trajectory of the PEG-electrolyte market?
The market is mature, recurring and price-sensitive. Revenue growth is likely to track procedure volume rather than unit-price expansion.
Revenue drivers
- Colonoscopy and gastrointestinal procedure volume.
- Aging populations and colorectal-cancer screening.
- Repeat surveillance colonoscopies.
- Hospital and ambulatory surgery-center purchasing.
- Generic substitution and formulary preference.
- Patient adherence to split-dose preparation.
Revenue pressures
- Generic price erosion.
- Conversion from 4-liter solutions to lower-volume products.
- Tablet-based alternatives.
- Private-label contracting.
- Tender and group-purchasing-organization pressure.
- Reduced reimbursement for ancillary prescription products.
- Patient intolerance, taste and incomplete preparation.
No public company separately reports revenue for GoLYTELY or the exact five-ingredient formulation. Bausch Health reports at segment and product-family levels rather than providing a standalone GoLYTELY revenue line. As a result, product-level revenue, margin and market-share estimates require commercial datasets rather than public financial statements.
The financial trajectory is best characterized as stable-to-declining for traditional branded volume, with persistent cash generation from brand recognition and established distribution. Generic suppliers face lower unit economics but can maintain volume through scale, contract manufacturing and portfolio distribution.
What generic entry risks exist for GoLYTELY?
Generic entry is already a structural feature of the market. The principal risks are continued substitution, reduced branded pricing power and loss of institutional contracts.
Generic launch scenarios
| Scenario |
Likely effect |
| Additional ANDA entrant |
Further price compression and share loss |
| Hospital contract rebid |
Rapid substitution toward lowest-cost supplier |
| Pharmacy-level generic substitution |
Reduced brand retention |
| Short-term supply disruption |
Temporary share recovery for available suppliers |
| Lower-volume product adoption |
Structural decline in 4-liter solution demand |
| Manufacturing quality event |
Recall, shortage or temporary competitor opportunity |
The largest operational risk is not a patent injunction. It is a quality, supply or manufacturing disruption involving a high-volume generic product. FDA manufacturing compliance, validated powder blending, electrolyte uniformity, packaging integrity and reconstitution instructions are central to supply continuity.
What patent litigation and Paragraph IV activity affect the product?
There is no widely recognized current patent litigation campaign that materially protects the core GoLYTELY formulation from generic competition. Paragraph IV activity is more commercially relevant for newer or differentiated bowel-preparation products, particularly lower-volume formulations and tablets with more recent patents.
For GoLYTELY-type products, litigation exposure is generally limited because:
- The active ingredients are old.
- The therapeutic use is established.
- The dosage form is technically straightforward.
- Multiple generic products are already marketed.
- Alternative formulations can avoid narrow claims.
A company evaluating entry should distinguish between patent litigation involving GoLYTELY itself and litigation involving competing products such as Suprep, Sutab or Plenvu. Those products may have more relevant formulation, dosage-regimen, tablet or method-of-use claims.
What manufacturing and intellectual-property barriers remain?
Manufacturing is the more significant barrier. The product requires accurate blending of multiple salts and PEG 3350, control of moisture and particle characteristics, validated filling, stability testing and packaging that preserves the powder until reconstitution.
Key manufacturing risks
- Content uniformity across the powder blend.
- Hygroscopicity and moisture control.
- Stability of bicarbonate and sulfate components.
- Accurate fill weight.
- Container-closure integrity.
- Large-volume reconstitution instructions.
- Taste and patient acceptability.
- FDA inspection readiness.
- Reliable supply of pharmaceutical-grade PEG 3350 and inorganic salts.
These controls can delay launch or create shortage risk, but they do not create durable exclusivity. A capable generic manufacturer can generally overcome them with established oral-solid and powder-blending infrastructure.
What licensing deals and commercial partnerships affect the market?
The category has limited licensing value because the core formulation is mature and genericized. Commercial arrangements are more likely to involve:
- Contract manufacturing.
- Private-label supply.
- Hospital and health-system purchasing agreements.
- Pharmacy benefit and wholesaler distribution.
- Brand portfolio transactions.
- Rights to newer bowel-preparation formulations.
The most material strategic asset is distribution access rather than patent ownership. A company with established gastroenterology sales coverage, ambulatory surgery-center contracts and pharmacy distribution can extract more value from the product than a standalone entrant with no channel relationships.
What is the competitive outlook for PEG 3350 electrolyte solution?
Demand should remain durable because colonoscopy and related procedures generate recurring need for bowel cleansing. The traditional 4-liter product category is unlikely to disappear, but its share can decline as clinicians and patients move toward lower-volume liquids and tablets.
The market outlook is:
- Volume: stable to modest growth with procedure demand.
- Price: declining under generic and institutional pressure.
- Brand share: vulnerable to substitution.
- Gross margin: higher for branded differentiated products than for standard generics.
- Patent protection: weak for the five-ingredient formulation.
- Regulatory risk: moderate, concentrated in manufacturing and labeling compliance.
- Commercial risk: high for suppliers without scale or contracts.
- Innovation: concentrated in tolerability, reduced volume, tablets and adherence.
Key Takeaways
- The five-ingredient formulation is the GoLYTELY-type PEG-electrolyte bowel preparation.
- FDA approval is associated with GoLYTELY NDA 018097.
- Core composition and standard bowel-cleansing use have little practical patent protection.
- Generic competition is established and is the principal source of price pressure.
- Revenue is tied to colonoscopy volume, payer substitution and product availability.
- Lower-volume liquids and tablet products are the main competitive threat.
- No standalone public revenue figure is reported for GoLYTELY or the exact formulation.
- Manufacturing quality, supply reliability and distribution contracts matter more than patent exclusivity.
- The market is commercially durable but financially mature, with limited pricing power.
FAQs
Is polyethylene glycol 3350 electrolyte solution the same as MiraLAX?
No. MiraLAX contains PEG 3350 without the complete sodium, potassium, chloride, bicarbonate and sulfate electrolyte system used in prescription lavage products. MiraLAX is generally used for constipation, while PEG-electrolyte lavage solutions are used for bowel cleansing before procedures.
Is GoLYTELY interchangeable with Suprep?
No. Both are bowel preparations, but they have different active ingredients, dosing instructions, fluid requirements and labeling. Substitution depends on the prescription, clinical judgment, payer coverage and patient-specific risks.
Does GoLYTELY have an active composition patent?
The commercial market indicates that the core formulation is no longer protected by an effective composition patent that prevents generic competition. Current patent analysis should separate expired patents from live, enforceable claims.
Are PEG-electrolyte bowel preparations biologics or biosimilars?
No. These are nonbiologic chemical drug products. Biosimilar approval pathways do not apply. Generic products generally enter through ANDA procedures and therapeutic-equivalence standards.
What is the largest commercial threat to traditional 4-liter PEG solutions?
The largest threat is substitution toward lower-volume liquids and tablet-based bowel preparations, combined with generic price competition. These products compete on tolerability and completion rather than on a different clinical purpose.
References
- U.S. Food and Drug Administration. (2024). GoLYTELY prescribing information. Braintree Laboratories, Inc.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: GoLYTELY, NDA 018097.
- Bausch Health Companies Inc. (2024). Annual report and Form 10-K.
- U.S. Food and Drug Administration. (2024). ANDA approvals and therapeutic equivalence evaluations for polyethylene glycol-electrolyte solutions.
